ABSTRACT
Clinical evaluation of thromboplastins manufactured by RENAM (Moscow) with international index of sensitivity (IIS) 1.1-1.5 and comparison of the results with the data obtained in the same patients with foreign thromboplastins (Dade, USA; Behring, Germany; Diamed, Switzerland) and Mediolab thromboplastins (Russia) manufactured from different raw materials (rabbit brain and human placenta) showed that by sensitivity to indirect anticoagulants, Russian thromboplastins made by RENAM and Mediolab firms are not inferior to the best foreign analogs.
Subject(s)
Prothrombin Time , Thrombolytic Therapy , Thromboplastin , Thrombosis/blood , Administration, Oral , Animals , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , Humans , International Normalized Ratio , Phenindione/administration & dosage , Phenindione/therapeutic use , Rabbits , Russia , Surgical Procedures, Operative , Thromboplastin/standards , Thrombosis/prevention & controlABSTRACT
Comparative analysis of foreign and Russian thromboplastins demonstrated differences in the notions "activity" and "sensitivity" and the significance of low value of International Index of Sensitivity (IIS). Sensitivity of thromboplastin manufactured by RENAM Firm, Russia (IIS = 1.5) to deficiency of prothrombin factors II, VII, X has been demonstrated, which means that this thromboplastin can be used for diagnosis of deficiency of each of these factors. The authors consider that testing of thromboplastin sensitivity to factor VII is the main criterion of its fitness for monitoring anticoagulant therapy.
Subject(s)
Thromboplastin/standards , Animals , Humans , Rabbits , Reference StandardsABSTRACT
A simple and sensitive method for estimation of activated partial thromboplastin time (APTT) is developed, making use a complex reagent containing the activator (plant phospholipids) and contact factor (ellagic acid). The test requires additionally only 0.025 M CaCl2. The test is more sensitive to the presence of heparin in the blood and to insufficiency of blood clotting factors VIII and IX than the reagents containing insoluble substances (kaolin and animal phosphatides). Addition of soluble ellagic acid into reagent for APTT estimation allows studies on optic coagulometers.
Subject(s)
Coagulation Protein Disorders/diagnosis , Ellagic Acid , Partial Thromboplastin Time , Blood Coagulation , Coagulation Protein Disorders/blood , HumansABSTRACT
The authors propose a modified single-stage method for measuring the activity of factor VIII in human plasma, consisting in the utilization of modern philosophy of standardization of coagulological studies, accepted at the National Reference Institute of Great Britain. The authors draw attention to plotting the line of tested plasma titration, which is to be parallel to the calibration curve.
Subject(s)
Factor VIII/analysis , Hematologic Tests/standards , Humans , Reference StandardsABSTRACT
Three kits of reagents manufactured by RENAM Research and Production Unit provide the analytical reliability of hemoglobinometry. The kits contain: 1) dry powder transforming agent; 2) four calibration standard solutions of hemoglobin cyanate requiring no dilution; 3) three highly purified stable solutions of hemoglobin (simulating human blood) with attested concentrations of hemoglobin from 50 to 200 g/liter.
Subject(s)
Hemoglobinometry/standards , Hemoglobinometry/methods , Hemoglobins , Humans , Reagent Kits, Diagnostic , Reproducibility of Results , SolutionsSubject(s)
Dextrans/toxicity , Plasma Substitutes/toxicity , Animals , Chinchilla , Guinea Pigs , MiceABSTRACT
Rats and rabbits were infused with solutions of hydroxyethyl starch (HES) with different physical and chemical properties. Large quantities of HES produced specific macrophage reaction in the spleen. When used in therapeutic doses (plasmaexpander) HES caused no macrophage reaction. HES proved to be non-toxic for the internal organs.
Subject(s)
Hydroxyethyl Starch Derivatives/toxicity , Starch/analogs & derivatives , Animals , Chemical Phenomena , Chemistry, Physical , Dose-Response Relationship, Drug , Infusions, Parenteral , Macrophages/drug effects , Macrophages/pathology , Rabbits , Rats , Solutions , Spleen/drug effects , Spleen/pathology , Time FactorsSubject(s)
Anthracenes , Hydroxyethyl Starch Derivatives/blood , Indicators and Reagents , Starch/analogs & derivatives , Animals , Kinetics , Methods , RabbitsSubject(s)
Hydroxyethyl Starch Derivatives/therapeutic use , Plasma Substitutes , Shock/therapy , Starch/analogs & derivatives , Alkylation , Animals , Biopolymers , Blood Coagulation/drug effects , Dextrans/therapeutic use , Drug Evaluation , Drug Evaluation, Preclinical , Hemorrhage/therapy , Humans , Hydroxyethyl Starch Derivatives/metabolism , Hydroxyethyl Starch Derivatives/toxicity , Kinetics , Molecular Conformation , Molecular Weight , Structure-Activity Relationship , Tissue DistributionSubject(s)
Anemia, Hypochromic/drug therapy , Hematinics , Animals , Chinchilla , Hematinics/therapeutic use , RabbitsABSTRACT
Experiments were conduced with a twofold purpose, viz--to determine the medium lethal dose of the preparation and to study the dextrafer distribution in tissues of rabbits after its single or repeated intravenous infusion. The medium lethal dose of the drug was found to be 250 time greater than its maximal therapeutic dose. Morphological and histochemical observations showed dextrafer to have no toxic effect on the rabbits' tissues over a period of 2 years after its single intravenous infusion.
